Gene Therapy for Cystic Fibrosis: Restoring CFTR Function

Cystic fibrosis (CF) is caused by mutations in the CFTR gene (chromosome 7), leading to defective chloride/bicarbonate transport. Gene therapy aims to deliver a functional CFTR copy to airway epithelial cells.

Approaches

VectorExamplesStatus
Viral (AAV, lentivirus)AAV2/5, AAV1, lentiviral pseudotypesPreclinical; AAV trials showed transient expression, immune responses
Non-viral (liposome, nanoparticle)GL67A/pGM169 (UK Cystic Fibrosis Gene Therapy Consortium)Phase 2b (2015): modest FEV₁ stabilization vs. placebo; not commercialized
mRNA / lipid nanoparticleTranslate Bio (MRT5005), ModernaPhase 1/2 ongoing; repeat dosing feasible
Gene editing (CRISPR/Cas)Base editing, prime editing of CFTR mutationsPreclinical; delivery to airway stem cells remains challenge

Key Challenges

  • Airway mucus barrier & rapid epithelial turnover (30–60 days) → need repeat dosing or stem cell targeting.
  • Immune response to vector/transgene.
  • Large CFTR cDNA (4.4 kb) exceeds AAV packaging limit (~4.7 kb with promoter) — requires dual vectors or truncated versions.
  • Need >5–10% corrected cells for clinical benefit.

Current Standard of Care

CFTR modulators (ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor, elexacaftor/tezacaftor/ivacaftor) treat ~90% of patients by rescuing mutant protein function. Gene therapy remains investigational for non-responders or ineligible genotypes.

Gene therapy for CF is a logical but still experimental strategy; modulator therapy has transformed outcomes for most.

Genetic Disorders - Related Articles